Ocular Therapeutix, Inc. (OCUL) Stock Price & Analysis

Ocular Therapeutix, Inc. (OCUL) closed at USD 6.61 on Thursday, October 22, 2026, up 2.01% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 6.48; the Oct 22, 2026 session ranged USD 6.4–6.67 on volume of 2,145,005 shares. Market capitalization is $1.45B, with a 52-week range of USD 6–16.44 (NGM). Source: Nexqual, retrieved October 23, 2026 at 10:31 UTC.

Also available as compact Markdown for AI agents: nexqual.com/OCUL.md

Key facts (OCUL)

• Last four reported quarters (through Jun 30, 2026): revenue $52.1M, net income -$301M (-579.1% margin), free cash flow -$255M (SEC filings).
• Insider open-market sales, last ~7 months: 13 Form 4 filings, $928K; 1 not under a Rule 10b5-1 plan ($11K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.67 on a 1–5 scale) (12 analysts), mean target USD 26 (range 14–34).
• Total return with dividends: 1Y -42.2% vs S&P 500 +14.9%; 5Y -4.3% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD -0.35, revenue estimate $14.3M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OCUL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (OCUL)

P/S 27.9x · EV/Sales 17.8x · P/B 2.8x · FCF yield -17.57% · Earnings yield -20.77% · Net cash $526M · EV $926M

Insider sales (SEC Form 4, open-market, last ~7 months) (OCUL)

12 of 13 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (OCUL)

Consensus Buy (mean 1.67 on a 1–5 scale), 12 analysts; mean target USD 26 (low 14, high 34).

Rating changes, last 120 days:

Total return (dividends reinvested) (OCUL)

OCUL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 5, 2026.

Companies that name OCUL in their SEC reports

OCUL company outlook (results filed Aug 3, 2026)

• “In a new post-hoc analysis of SOL-1 data applying the SOL-R rescue criteria of >5 ETDRS letter loss and ≥75 µm CSFT increase from baseline, we estimate a treatment burden reduction of up to 72% as compared to a projected on-label dosing regimen of aflibercept (2 mg) over 60 weeks.”
• “Post-hoc Analysis of SOL-1 (Phase 3, wet AMD) demonstrates up to an estimated 72% reduction in treatment burden over 60 weeks with AXPAXLI relative to a projected on-label dosing regimen of aflibercept (2 mg) every 8 weeks.”
• “The total estimated mean injection burden with AXPAXLI represents a 72% reduction counting from the first screening visit at Week -8 excluding loading doses and a 56% reduction when loading doses are included, as compared to a projected on-label dosing regimen of aflibercept (2 mg) with no rescues. ·”
• “Following these changes, topline SOL-R results are now expected in the first quarter of 2028.”

Quoted word-for-word from the SEC 8-K results press release.

OCUL analyst estimates and revisions

OCUL options: expected move

Options price a move of about ±17.0% (±$1.13) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7.6% on average.

30-day implied volatility 71% vs 86.5% realized over the last 30 trading days. Put/call ratio (volume) 0.08. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:31 UTC)

Technical Analysis (OCUL)

Nexqual's technical model rates OCUL "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:31 UTC.

Analyst Ratings (OCUL)

Wall Street analysts rate OCUL "Buy" based on 12 analysts, with a mean price target of USD 26 (range USD 14–34), per Nexqual as of October 23, 2026 at 10:31 UTC.

Earnings (OCUL)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:31 UTC.

Financials & Fundamentals (OCUL)

Source: Nexqual, October 23, 2026 at 10:31 UTC.

Financial Health Score (OCUL)

Nexqual rates Ocular Therapeutix, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:31 UTC.

Ownership (OCUL)

Source: Nexqual, October 23, 2026 at 10:31 UTC.

Leadership (OCUL)

Ocular Therapeutix, Inc. is led by Pravin U. Dugel, Executive Chairman, President & CEO, per Nexqual as of October 23, 2026 at 10:31 UTC.

Major Backers & Investors (OCUL)

Notable institutional backers of Ocular Therapeutix, Inc. include FMR, LLC, Deep Track Capital, Lp, Fidelity, according to Nexqual as of October 23, 2026 at 10:31 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:31 UTC.

From Ocular Therapeutix, Inc.'s Latest SEC 10-K Filing (filed 2026-02-05)

Key Strengths & Strategy (as disclosed to the SEC)

• AXPAXLI is seeking to address segments of the exudative retinal diseases market, which in the aggregate is estimated to include up to 8.3 million patients in the United States by 2030 and accounted for approximately $9.4 billion in U.S. annual estimated revenues in 2025, according to the Market Scope 2025 Exudative Retinal Disease Pharmaceuticals Report, published in October 2025, or the Market Scope 2025 Retina Report.
• According to the Market Scope 2025 Retina Report, there were approximately 14.8 million people globally and 1.7 million people in the United States who suffered from wet AMD in 2025, and this population is expected to grow at a 3.0% and 3.3% compound annual growth rate, or CAGR, respectively, through 2030.
• In a written Type C response received in August 2024, and a subsequent written response received in December 2024, the FDA agreed that the SOL-R repeat dosing wet AMD trial, with a primary endpoint at Week 56, should be appropriate as an adequate and well-controlled trial in support of a potential NDA and product label for AXPAXLI for the treatment of wet AMD.
• At the time, the FDA also noted that the use of one superiority trial and one non-inferiority trial is generally acceptable as the basis of an eventual NDA in wet AMD.

Partnerships

• We are conducting the SOL-1 trial in accordance with a SPA agreement with the FDA.
• We hold worldwide exclusive commercial rights to the core technology underlying all of our product candidates in development and have not granted commercial rights to any marketing partners other than a license agreement and collaboration with AffaMed Therapeutics Limited, or AffaMed, for the development and commercialization of DEXTENZA and OTX-TIC in certain geographies in Asia agreed to between the parties.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.
• Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we develop.
• Any manufacturing defect or error discovered after products have been produced and distributed could result in significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation and potential for product liability claims.
• We may become involved in lawsuits to protect or enforce our licensed and owned patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:31 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt